Michael Landsittel
CIK: 0001651036
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Mar 23, 2026DMRA
Damora Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
37.3K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Award(A)Direct21.4K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Disposition(D)Direct51.1K shares- - Jul 17, 2025BPMC
Blueprint Medicines Corp
Tender Offer(U)Direct43.2K shares- - Mar 5, 2025BPMC
Blueprint Medicines Corp
Sale(S)Direct5.3K shares at avg. $88.80$469K - Mar 1, 2025BPMC
Blueprint Medicines Corp
Award(A)Direct11K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Mar 23, 2026 |  DMRA Damora Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 37,313 | - | - | Direct |
| Jul 17, 2025 |  BPMC Blueprint Medicines Corp | Award(A) | 21,353 | - | - | Direct |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | Disposition(D) | 51,102 | - | - | Direct |
| Jul 17, 2025 | BPMC Blueprint Medicines Corp | Tender Offer(U) | 43,175 | - | - | Direct |
| Mar 5, 2025 | BPMC Blueprint Medicines Corp | Sale(S) | 5,284 | $88.80 | $469,219 | Direct |
| Mar 1, 2025 | BPMC Blueprint Medicines Corp | Award(A) | 11,000 | - | - | Direct |
1-6 of 6 transactions
About Landsittel Michael
Landsittel Michael (SEC CIK 0001651036) files insider reports with the SEC as Director of Damora Therapeutics, Inc. (DMRA) and CHIEF FINANCIAL OFFICER of Blueprint Medicines Corp (BPMC).
Signal8 holds 5 ownership filings by Landsittel Michael (1 Form 3, 4 Form 4), filed between Mar 4, 2025 and Mar 25, 2026. Those filings report 6 transactions, from Mar 1, 2025 to Mar 23, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Landsittel Michael's filings is in WALTHAM, MA.
Recent filings by Landsittel Michael
- Mar 23, 2026: Grant or award of DMRA derivative securities (Form 4, code A).
- Jul 17, 2025: Grant or award of BPMC shares (Form 4, code A).
- Jul 17, 2025: Disposition to issuer transaction of BPMC shares (Form 4, code D).
- Jul 17, 2025: Tender of shares transaction of BPMC shares (Form 4, code U).
- Mar 5, 2025: Open-market sale of BPMC shares (Form 4, code S).
Other insiders filing for Damora Therapeutics, Inc. (DMRA)
- Jarrett Jennifer, Director, President and CEO
- Cheng Andrew, Director
- Winslow Garrett, General Counsel
- Burkavage Brian, SVP, Finance
- Turtle Cameron, Director
- Fairmount Funds Management LLC, Director